Rochester, NY 6/5/2009 8:40:43 AM
End of Day Market Movers - G-III Apparel Group, LTD.,GIII - GS Financial Corp.,GSLA - OncoGenex Pharmaceuticals Inc.,OGXI - ACADIA Pharmaceuticals Inc.,ACAD
G-III Apparel Group Ltd. - OncoGenex Pharmaceuticals, Inc. - ACADIA Pharmaceuticals Inc.
End of Day Market Movers - G-III Apparel Group, LTD.,GIII - GS Financial Corp.,GSLA - OncoGenex Pharmaceuticals Inc.,OGXI - ACADIA Pharmaceuticals Inc.,ACAD
G-III Apparel Group, LTD.,GIII
G-III Apparel Group Ltd. designs, manufactures, imports, and markets a range of outerwear, sportswear apparel, and accessories to retailers primarily in the United States. It offers coats, jackets, and pants, as well as women"s leather and textile apparel, including jackets, skirts, and related sportswear separates; women suits and dresses; accessories, such as women"s handbags and men"s carrying cases; and women"s and men"s luxury outerwear, including leather outerwear. The company also produces apparel under its own proprietary brands, including Andrew Marc, Marc New York, Marvin Richards, Jessica Howard, Eliza J, Black Rivet, Siena Studio, Tannery West, G-III by Carl Banks, and Winlit. It sells its products under licensed brands, own proprietary brands, and private retail labels.
Last Trade: 10.37
Day's Range: 9.16 - 10.47
52wk Range: 3.24 - 20.58
Volume: 379,282
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
OncoGenex Pharmaceuticals Inc.,OGXI
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company"s lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The company"s preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington.
Last Trade: 25.02
Day's Range: 20.80 - 25.70
52wk Range: 2.00 - 25.70
Volume: 1,199,397
---
ACADIA Pharmaceuticals Inc.,ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Eighth Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 9:30 a.m. Eastern Time at The New York Palace Hotel in New York City.
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is currently developing a portfolio consisting of its five most advanced product candidates including pimavanserin, which is in Phase III development for Parkinson’s disease psychosis in collaboration with Biovail. In addition to pimavanserin, ACADIA has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as two programs in IND-track development.
Last Trade: 3.10
Day's Range: 2.45 - 3.10
52wk Range: 0.50 - 7.28
Volume: 253,930
----
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
